SLXN
Silexion Therapeutics Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.38
P/S
0.00
EV/EBITDA
0.41
DCF Value
$3.59
FCF Yield
-1678.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-387.8%
ROA
-165.1%
ROIC
-250.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-4.4M | $-1.41 |
| FY 2025 | $0.00 | $-11.9M | $-8.96 |
| Q3 2025 | $0.00 | $-3.3M | $2.88 |
| Q2 2025 | $0.00 | $-2.5M | $4.32 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.06
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.